Skip to main content

Ask your doctor about a switch to Esperoct®.

Experience the Esperoct® difference–with less frequent dosing and higher factor levels compared with standard half-life products.

Man working out outside
Man working out outside

Esperoct® is designed to provide high factor levels and proven protection from bleeds compared with standard half-life products.

factor levels above 3% statistic
factor levels above 3% statistic
factor levels above 5% statistic
factor levels above 5% statistic

aTrough level goal is 1% for prophylaxis.
bData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18years) were 2.7 IU/dL.
cSteady-state factor VIII (FVIII) activity levels were estimated in 143 adults and adolescents using PK modeling.

Are you a Commander or an Investigator?

Learn more about your treatment personality type.

Your approach to treating hemophilia A can vary based on your personality. Take our 5-question quiz to discover your “treatment personality” type—and unlock insights to help you get the most out of your therapy.

Take the quiz

Half-life image
Half-life image

Are you a Commander or an Investigator?

Learn more about your treatment personality type.

Your approach to treating hemophilia A can vary based on your personality. Take our 5-question quiz to discover your “treatment personality” type—and unlock insights to help you get the most out of your therapy.

Take the quiz

Switch to fewer infusions.

Compared with standard half-life dosing schedules, the simple, fixed dosing routine of Esperoct® calls for fewer infusions per year.

Esperoct® infusion dosing in adults and adolescents
Esperoct® infusion dosing in adults and adolescents

No dose adjustment needed

If you previously infused every other day

If you previously infused 3x/week

Rolled up jump rope
Esperoct® infusion dosing in children ages 0 to 12 years
Esperoct® infusion dosing in children ages 0 to 12 years

No dose adjustment needed.d

If your child previously infused every other day

If your child previously infused 3x/week

dInterval can be adjusted based on individual response to treatment.

castle with flags
Male and female Hemophilia Community Liaisons

Where can Esperoct®
take you?

Even parts of Alaska reach summer temps above 90°F. Esperoct® is the only EHL product that can be stored from 86°F up to 104°F for up to 3 months. Wherever you go, Esperoct® can take the heat.

Male and female Hemophilia Community Liaisons

Connect with your HCL.

Questions about switching to Esperoct®? Connect with your Hemophilia Community Liaison (HCL) for personalized support in your journey with hemophilia A. Find your HCL now.

Esperoct® FAQs
Esperoct® FAQs

Your questions, answered.

Question: What is a trough level?

Answer: Factor in the bloodstream rises and falls in patients treated prophylactically with factor. It is highest right after an infusion and lowest right before an infusion. The low level right before infusion is called the trough level. Many factor products aim to keep trough levels at 1%. In a study of adults and adolescents who were treated with Esperoct® for prophylaxis, researchers found that extended half-life Esperoct® keeps trough levels at or above 3% (moderate hemophilia) all of the time, and 5% (mild hemophilia) approximately 90% of the time, based on PK modeling.e,f,g

Question: Why is knowing a product’s half-life important?

Answer: Measuring a factor’s half-life gives doctors, patients and caregivers the opportunity to compare the factor activity level of different products by calculating the time it takes the body to metabolize or inactivate half the amount of factor.

How long factor stays in the blood, however, is only half the battle. The other consideration is the factor level. The extended half-life of Esperoct® (22 hours on average in adults) offers higher factor levels for longer compared to standard half-life products.h

eTrough level goal is 1% for prophylaxis.

fData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.

gSteady-state factor VIII (FVIII) activity levels were estimated in 143 adults and adolescents using PK modeling.

hData shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.

Selected Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face
What should I tell my healthcare provider before using Esperoct®?
  • Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®
What are the possible side effects of Esperoct®?
  • Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Prescribing Information.

Esperoct® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.